Douglas French
Co-Founder and Managing Director @ Sante Ventures
Austin, United States
Douglas French is a Series A investor at Sante Ventures in Austin focused on Medical and Hospital. Douglas French is the Managing Director at Santé Health Ventures.
- Total investments:
- 9
- Last investment:
- Lead investor:
- 56%
Last updated:
For AI agents: llms.txt
Industries Douglas French invests in
MedicalHospitalHealth CareOncologyMarketing
Stages Douglas French invests in
Series ASeries BSeries CSeries DFunding Round
Countries Douglas French invests in
United States
Investment Focus
Industry
- Medical 2 (22%)
- Hospital 2 (22%)
- Health Care 2 (22%)
- Oncology 1 (11%)
- Marketing 1 (11%)
Stage
- Series A 2 (22%)
- Series B 2 (22%)
- Series C 1 (11%)
- Series D 1 (11%)
- Funding Round 1 (11%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Brado
|
Brado is an insight-driven brand growth firm. | Venture - Series Unknown / Jan 09, 2026 | |
Reimagine Care
|
Reimagine Care is a health care company that provides technology-enabled services to support community-based oncology care settings. It aims to make high-quality cancer care more affordable, accessible, and patient-centric. Reimagine Care partners with HC systems and independent physician oncology practices to support value-based oncology caredelivery in the community. They do this by providing the people, processes, and a robust technology platform that enables the scalable and effective delivery of high-quality, patient-centric, lower-cost cancer care across multiple care sites, including the home.It was founded in 2020 and is based in Nashville, Tennessee. | $25M / Series A / Jan 25, 2022 | |
EndoStim
|
EndoStim is a medical device company developing therapeutics for gastrointestinal and urological neuro-muscular disorders. It is performing clinical trials to pursue FDA approval for a new treatment for sphincter-related disorders such as gastroesophageal reflux disease (GERD) and urinary urge incontinence. Its microstimulator technology provideslong-term reflux control by restoring normal esophageal function that directly targets the patient's weak or dysfunctional lower esophageal sphincter (LES) muscle between the stomach and the esophagus and enable patients to reduce or avoid typical gastrointestinal side effects of traditional anti-reflux surgery. | $25M / Series D / May 12, 2016 | |
RiseHealth
|
Rise Health, Inc., a healthcare services company, provides primary care solutions to help physician practices and other healthcare organizations in the United States. It allows patients to access primary care when they need; creates care experience for patients that provides the opportunity to engage with their primary care provider and managetheir health; provides tools and support for physicians to manage the health of their patients; and leverages physicians' time and skills. The company also offers customers the tools, information, and capabilities to develop the infrastructure needed to participate in accountable care organizations and to support the precepts of a patient centered medical home. Rise Health, Inc. was formerly known as Optizend, Inc. The company was incorporated in 2009 and is based in Chicago, Illinois. | $3M / Series B / Jul 25, 2013 | |
|
EndoStim
|
EndoStim is a medical device company developing therapeutics for gastrointestinal and urological neuro-muscular disorders. It is performing clinical trials to pursue FDA approval for a new treatment for sphincter-related disorders such as gastroesophageal reflux disease (GERD) and urinary urge incontinence. Its microstimulator technology provideslong-term reflux control by restoring normal esophageal function that directly targets the patient's weak or dysfunctional lower esophageal sphincter (LES) muscle between the stomach and the esophagus and enable patients to reduce or avoid typical gastrointestinal side effects of traditional anti-reflux surgery. | $14.1M / Series D / Jun 05, 2013 | |
|
EndoStim
|
EndoStim is a medical device company developing therapeutics for gastrointestinal and urological neuro-muscular disorders. It is performing clinical trials to pursue FDA approval for a new treatment for sphincter-related disorders such as gastroesophageal reflux disease (GERD) and urinary urge incontinence. Its microstimulator technology provideslong-term reflux control by restoring normal esophageal function that directly targets the patient's weak or dysfunctional lower esophageal sphincter (LES) muscle between the stomach and the esophagus and enable patients to reduce or avoid typical gastrointestinal side effects of traditional anti-reflux surgery. | $9.1M / Series C / Jan 14, 2013 | |
|
EndoStim
|
EndoStim is a medical device company developing therapeutics for gastrointestinal and urological neuro-muscular disorders. It is performing clinical trials to pursue FDA approval for a new treatment for sphincter-related disorders such as gastroesophageal reflux disease (GERD) and urinary urge incontinence. Its microstimulator technology provideslong-term reflux control by restoring normal esophageal function that directly targets the patient's weak or dysfunctional lower esophageal sphincter (LES) muscle between the stomach and the esophagus and enable patients to reduce or avoid typical gastrointestinal side effects of traditional anti-reflux surgery. | $5.5M / Dec 05, 2011 | |
|
EndoStim
|
EndoStim is a medical device company developing therapeutics for gastrointestinal and urological neuro-muscular disorders. It is performing clinical trials to pursue FDA approval for a new treatment for sphincter-related disorders such as gastroesophageal reflux disease (GERD) and urinary urge incontinence. Its microstimulator technology provideslong-term reflux control by restoring normal esophageal function that directly targets the patient's weak or dysfunctional lower esophageal sphincter (LES) muscle between the stomach and the esophagus and enable patients to reduce or avoid typical gastrointestinal side effects of traditional anti-reflux surgery. | $6M / Series B / Jul 19, 2010 | |
|
RiseHealth
|
Rise Health, Inc., a healthcare services company, provides primary care solutions to help physician practices and other healthcare organizations in the United States. It allows patients to access primary care when they need; creates care experience for patients that provides the opportunity to engage with their primary care provider and managetheir health; provides tools and support for physicians to manage the health of their patients; and leverages physicians' time and skills. The company also offers customers the tools, information, and capabilities to develop the infrastructure needed to participate in accountable care organizations and to support the precepts of a patient centered medical home. Rise Health, Inc. was formerly known as Optizend, Inc. The company was incorporated in 2009 and is based in Chicago, Illinois. | $4M / Series A / Mar 06, 2009 |
Co-Investors
About Sante Ventures
Santé Ventures is a life sciences venture capital firm that invests exclusively in early-stage companies developing innovative new medical technologies or healthcare delivery models. The firm was founded in 2006 and has nearly $1 billion in capital under management.
Sante Ventures Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Casey Cunningham
Partner & Chief Scientific Officer
|
|||
David Kaufman
Chief Operating Officer
|
|||
Dennis McWilliams
Managing Director
|
|||
Diane Brouilliard
Head of Talent & Networks
|
|||
|
Douglas French
Co-Founder and Managing Director
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
Enterprise Investors
77,348 investors
Health Care Investors
43,014 investors
Medical Investors
18,848 investors
Enterprise VC Funds
49,693 investors
Health Care VC Funds
32,370 investors
Medical VC Funds
16,214 investors
Enterprise Investors in United States
37,530 investors
Health Care Investors in United States
21,541 investors
Medical VC Funds in United States
7,585 investors
FAQ
What does Douglas French invest in?
Douglas French invests primarily in Medical, Hospital and Health Care startups, most often at Series A and Series B stage. Most of the 9 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Douglas French last invest?
The most recent investment recorded for Douglas French closed in Jan 2026. Shizune tracks 9 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
